Aura Biosciences, Inc.
AURANext catalyst
AU-011
Eye Cancer
Get an email about AURA's next catalysts
Track Aura Biosciences (AURA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 4 past
How AURA's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bel-sar | Phase 3 | Choroidal Melanoma | - | - |
Light-activated AU-011 | Phase 2 | Uveal Melanoma | - | - |
AU-011 | Phase 2 | Eye Cancer | - | - |
Frequently asked questions
What is in Aura Biosciences, Inc.'s drug pipeline?β
CatalystAlert tracks 3 drug candidates in Aura Biosciences, Inc.'s (AURA) pipeline across Phase 3, Phase 2. Its lead program is Bel-sar (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aura Biosciences, Inc.'s next FDA catalyst?β
Aura Biosciences, Inc.'s (AURA) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AURA biotech catalysts?β
Add AURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aura Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
